Referenties

1. Gecse KB, et al. J Crohns Colitis 2016;10(2):133-40. 
2. Jørgensen KK, et al. Lancet 2017;389:2304-16. 
3. QuintilesIMS. MIDAS, February 2017. 
4. INFLECTRA® Summary of Product Characteristics. 
5. European Public Assessment Report: INFLECTRA®. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002778/WC500151490.pdf. Accessed December 2017. 
6. European Medicines Agency. Guidelines on similar biological medicinal products containing monoclonal antibodies – non-clinical and clinical issues. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdf. Accessed December 2017. 
7. Yoo DH. Expert Rev Clin Immunol 2017;13(7):653-66. 
8. Danese S, et al. Aliment Pharmacol Ther 2011;33:857-69.  
9. Moss AC. Gastroenterol Rep 2015;3(1):63-8. 
10. FDA. CBER approval letter, infliximab. 1998. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/1998/inflcen082498L.html.
Accessed December 2017. 
11. EMA. Public Statement on Remicade (infliximab). 2000. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/08/news_detail_001098. jsp&mid=WC0b01ac058004d5c1. Accessed December 2017. 
12. Medscape. [Public Release: 22 September 2005]. https://www.medscape.com/viewarticle/513282. Accessed December 2017. 
13. EMA. Remicade Scientific Discussion. 2006. 
14. Centocor, Inc. [Public Release: 6 November 2007]. https://www.eurekalert.org/pub_releases/2007-11/ci-rbf110607.php. Accessed December 2017. 
15. Remicade (infliximab). www.remicade.com. Accessed December 2017.
16. Gomollon F, et al. J Crohns Colitis 2016;1-26. 
17. Dignass A, et al. J Crohns Colitis 2012;6:991-1030.
18. Danese S, et al. J Crohns Colitis 2017;11:26-34.
20. Fiorino G, et al. Inflamm Bowel Dis 2017;23:233-43.
24. Farkas K, et al. J Crohns Colitis 2016;10:1273-8. 
25. Hlavaty T, et al. Gastroenterol Hepatol 2016;70:27-32. 
26. Jahnsen J, et al. Expert Rev Gastroenterol Hepatol 2015;9(S1):S45-52. 
27. Keil R, et al. Scand J Gastroenterol 2016;51:1062-8. 
28. UK inflammatory bowel disease (IBD) programme steering group. Royal College of Physicians, UK. IBD Biological Therapy Audit 2016. Available at: https://www.rcplondon.ac.uk/projects/outputs/national-clinical-audit-biological-therapies-annual-report-2016. Accessed December 2017. 
29. Razanskaite V, et al. J Crohns Colitis 2017 Jan 27 epub. 
30. Smits LJ, et al. J Crohns Colitis 2016;10:1287-93. 
31. ClinicalTrials.gov. NCT02096861. Available at: https://clinicaltrials.gov/ct2/show/NCT02096861?term=CT-P13&rank=1. Accessed December 2017. 
35. Alfonso J, et al. Ther Adv Gastroenterol 2017;10(9):661-71. 
36. Gonczi L, et al. Inflamm Bowel Dis 2017;23(11):1908-15.
37. Arguelles-Arias F, et al. Eur J Gastroenterol Hepatol 2017;29(11):1290-5.
38. Avouac J, et al. Semin Arthritis Rheum 2017. [Epub ahead of print.]
39. Balint A, et al. Expert Opin Drug Saf 2017;16(8):885-90.
40. Boone NW, et al. Eur J Clin Pharmacol 2018. [Open online access.]
41. Eberl A, et al. Scand J Gastroenterol 2017;52(12):1348-53.
42. Farkas K, et al. Expert Opin Biol Ther 2017;17(11):1325-32.
43. Guerrero Puente L, et al. Gastroenterol Hepatol 2017;40(9):595-604.
44. Kang B, et al. Inflamm Bowel Dis 2018. [Epub ahead of print]
45. Richmond L, et al. Arch Dis Child 2018;103(1):89-91.
46. Schmitz EMH, et al. Aliment Pharacol Ther 2018;47(3):356-63.
47. Smits L, et al. Dig Dis Sci 2017;62(11):3117-22.
48. Tokhadze N, et al. J Pharm Biomed Anal 2018;150:386-95.
49. Strik AS et al. Lancet Gastroenterol Hepatol 2018; 3: 404-412.

PP-IFA-NLD-0096